Skip to main content
Top
Published in: Supportive Care in Cancer 10/2016

Open Access 01-10-2016 | Original Article

Patient and health care provider perceptions of cancer-related fatigue and pain

Authors: Loretta A. Williams, Chet Bohac, Sharon Hunter, David Cella

Published in: Supportive Care in Cancer | Issue 10/2016

Login to get access

Abstract

Purpose

In 1997, Vogelzang et al. reported that 61 % of patients with cancer indicated fatigue impacted daily life more than pain, and only 37 % of oncologists shared this perception. We provide an update to this study, which can help prioritize symptom assessment and management in the clinic. Study aims were to determine and compare perceptions of patients with cancer and health care providers (HCPs) of the impact of fatigue and pain.

Methods

A random sample of patients with cancer was recruited in the USA by Harris Poll Online and Schlesinger Associates. Oncology HCPs were recruited by Food and Drug Research, Inc. and Toluna, Inc.

Results

From June to November 2012, 550 of 1122 eligible patients (49 %), 400 of 533 eligible oncologists (75 %), and 400 of 617 eligible oncology nurses (65 %) completed a survey. Of patients, 58 % reported that fatigue affected their daily lives more than pain while undergoing treatment with chemotherapy versus 29 % of oncologists and 25 % of oncology nurses that had this perception. Ninety-eight percent of patients reported experiencing fatigue, whereas 72 % of oncologists and 84 % of oncology nurses thought this was the case. Eighty-six percent of patients reported pain while undergoing treatment with chemotherapy, whereas 36 % of oncologists and 51 % of oncology nurses believed this occurred. Nausea and vomiting felt by HCPs were the most concerning symptoms for patients (88 %).

Conclusions

This study shows the importance of assessing symptoms by direct patient report during chemotherapy treatment. HCPs continue to underestimate the prevalence and importance of fatigue and pain for patients with cancer, a finding that may alter the management of treatment-related symptoms and may influence the development of patient symptom management plans.
Appendix
Available only for authorised users
Literature
1.
go back to reference Richardson A (1995) Fatigue in cancer patients: a review of the literature. Eur J Cancer Care 4(1):20–32CrossRef Richardson A (1995) Fatigue in cancer patients: a review of the literature. Eur J Cancer Care 4(1):20–32CrossRef
2.
go back to reference Cella D, Davis K, Breitbart W et al (2001) Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 19(14):3385–3391PubMed Cella D, Davis K, Breitbart W et al (2001) Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 19(14):3385–3391PubMed
3.
go back to reference Cella D, Lai JS, Chang CH et al (2002) Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 94(2):528–538CrossRefPubMed Cella D, Lai JS, Chang CH et al (2002) Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 94(2):528–538CrossRefPubMed
4.
go back to reference Demetri GD, Kris M, Wade J et al (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16(10):3412–3425PubMed Demetri GD, Kris M, Wade J et al (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16(10):3412–3425PubMed
5.
go back to reference Curt GA, Breitbart W, Cella D et al (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist 5(5):353–360CrossRefPubMed Curt GA, Breitbart W, Cella D et al (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist 5(5):353–360CrossRefPubMed
6.
go back to reference Littlewood TJ, Bajetta E, Nortier JW et al (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19(11):2865–2874PubMed Littlewood TJ, Bajetta E, Nortier JW et al (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19(11):2865–2874PubMed
7.
go back to reference Vogelzang NJ, Breitbart W, Cella D et al (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The fatigue coalition. Semin Hematol 34(3 Suppl 2):4–12PubMed Vogelzang NJ, Breitbart W, Cella D et al (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The fatigue coalition. Semin Hematol 34(3 Suppl 2):4–12PubMed
8.
go back to reference Basch E, Iasonos A, McDonough T et al (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7(11):903–909CrossRefPubMed Basch E, Iasonos A, McDonough T et al (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7(11):903–909CrossRefPubMed
9.
go back to reference Fromme EK, Eilers KM, Mori M et al (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 22(17):3485–3490CrossRefPubMed Fromme EK, Eilers KM, Mori M et al (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 22(17):3485–3490CrossRefPubMed
10.
go back to reference Fisch MJ, Lee JW, Weiss M et al (2012) Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol 30(16):1980–1988CrossRefPubMedPubMedCentral Fisch MJ, Lee JW, Weiss M et al (2012) Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol 30(16):1980–1988CrossRefPubMedPubMedCentral
11.
go back to reference Gilbert A, Sebag-Montefiore D, Davidson S et al (2015) Use of patient-reported outcomes to measure symptoms and health related quality of life in the clinic. Gynecol Oncol 136(3):429–439CrossRefPubMed Gilbert A, Sebag-Montefiore D, Davidson S et al (2015) Use of patient-reported outcomes to measure symptoms and health related quality of life in the clinic. Gynecol Oncol 136(3):429–439CrossRefPubMed
12.
go back to reference Basch E (2014) The rationale for collecting patient-reported symptoms during routine chemotherapy. Am Soc Clin Oncol Educ Book 2014:161–165CrossRef Basch E (2014) The rationale for collecting patient-reported symptoms during routine chemotherapy. Am Soc Clin Oncol Educ Book 2014:161–165CrossRef
13.
go back to reference Bennett AV, Jensen RE, Basch E (2012) Electronic patient-reported outcome systems in oncology clinical practice. CA Cancer J Clin 62(5):337–347CrossRefPubMed Bennett AV, Jensen RE, Basch E (2012) Electronic patient-reported outcome systems in oncology clinical practice. CA Cancer J Clin 62(5):337–347CrossRefPubMed
14.
go back to reference Wu AW, Kharrazi H, Boulware LE et al (2013) Measure once, cut twice—adding patient-reported outcome measures to the electronic health record for comparative effectiveness research. J Clin Epidemiol 66(8 Suppl):S12–S20CrossRefPubMedPubMedCentral Wu AW, Kharrazi H, Boulware LE et al (2013) Measure once, cut twice—adding patient-reported outcome measures to the electronic health record for comparative effectiveness research. J Clin Epidemiol 66(8 Suppl):S12–S20CrossRefPubMedPubMedCentral
15.
go back to reference Hughes EF, Wu AW, Carducci MA et al (2012) What can I do? Recommendations for responding to issues identified by patient-reported outcomes assessments used in clinical practice. J Support Oncol 10(4):143–148CrossRefPubMedPubMedCentral Hughes EF, Wu AW, Carducci MA et al (2012) What can I do? Recommendations for responding to issues identified by patient-reported outcomes assessments used in clinical practice. J Support Oncol 10(4):143–148CrossRefPubMedPubMedCentral
18.
go back to reference Cramp F, Daniel J (2008) Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 2:CD006145PubMed Cramp F, Daniel J (2008) Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 2:CD006145PubMed
19.
20.
go back to reference Paoli CJ, Bach BA, Quach D et al (2014) Performance status of real-world oncology patients before and after first course of chemotherapy. J Community Support Oncol 12:163–170CrossRef Paoli CJ, Bach BA, Quach D et al (2014) Performance status of real-world oncology patients before and after first course of chemotherapy. J Community Support Oncol 12:163–170CrossRef
Metadata
Title
Patient and health care provider perceptions of cancer-related fatigue and pain
Authors
Loretta A. Williams
Chet Bohac
Sharon Hunter
David Cella
Publication date
01-10-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 10/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3275-2

Other articles of this Issue 10/2016

Supportive Care in Cancer 10/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine